Tom Shepherd

Captor Therapeutics is a publicly-listed (WSE:CTX) innovative drug discovery and development company focused on targeting the undruggable proteome using targeted protein degradation. Our mission is to transform lives of patients suffering from cancer, autoimmunity and neurodegenerative diseases. Our groundbreaking technology is perfectly suited to create new drug candidates with the potential to ease patients' burden and cure conditions that so far have only been poorly treatable.